Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Retained Earnings (2016 - 2025)

Historic Retained Earnings for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$933.4 million.

  • UroGen Pharma's Retained Earnings fell 2142.42% to -$933.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$933.4 million, marking a year-over-year decrease of 2142.42%. This contributed to the annual value of -$806.2 million for FY2024, which is 1867.58% down from last year.
  • Per UroGen Pharma's latest filing, its Retained Earnings stood at -$933.4 million for Q3 2025, which was down 2142.42% from -$900.0 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Retained Earnings high stood at -$382.4 million for Q1 2021, and its period low was -$933.4 million during Q3 2025.
  • For the 5-year period, UroGen Pharma's Retained Earnings averaged around -$638.3 million, with its median value being -$631.5 million (2023).
  • As far as peak fluctuations go, UroGen Pharma's Retained Earnings plummeted by 4387.57% in 2021, and later plummeted by 1717.67% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Retained Earnings stood at -$467.3 million in 2021, then fell by 23.49% to -$577.1 million in 2022, then decreased by 17.72% to -$679.3 million in 2023, then dropped by 18.68% to -$806.2 million in 2024, then decreased by 15.77% to -$933.4 million in 2025.
  • Its last three reported values are -$933.4 million in Q3 2025, -$900.0 million for Q2 2025, and -$850.1 million during Q1 2025.